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Abstract
Background: Brain-derived neurotrophic factor (BDNF) has been reported to promote tumorigenesis and progression
in several human malignancies. The purpose of this study was to explore the function of BDNF in lung squamous cell
carcinoma (SCC) and adenocarcinoma (ADC).
Methods: The expression of BDNF was examined in 110 samples of lung SCC and ADC by immunohistochemistry. The
protein level of BDNF was examined in 25 lung SCC or ADC samples and paired non-tumors by western blot. BDNF
expression was also evaluated in human bronchial epithelial cells (HBE) and 4 lung cancer cell lines using western blot.
Three BDNF mRNA variants containing exons IV, VI and IX were evaluated in HBE, two SCC (SK, LK2) and two ADC
(A549, LTE) cell lines by RT-PCR. The expression and secretion of BDNF were also determined in cells using western blot
and ELISA. Then the shRNA specific for BDNF was transfected into LK2 or A549 cells to further elucidate the BDNF
knockdown on cell proliferation, apoptosis and invasion, which were confirmed by MTT, flow cytometry and transwell
examinations.
Results: 71.8 % (79 out of 110) of lung SCC and ADC samples were detected positive BDNF, and high expression of
BDNF was significantly correlated with histological type and T stage. Compared with non-tumorous counterparts, BDNF
was apparently overexpressed in SCC and ADC tissues. In cell studies, the extensive expression and secretion of BDNF
were demonstrated in lung cancer cells compared with HBE cells. Interestingly, the expressions of BDNF mRNA variant
IV and VI were identical in all cells examined. However, more expression of BDNF mRNA variant IX was found in SK and
LK2 cells. The apoptotic cells were increased, and the cell proliferation and invasion were both attenuated once the
expression of BDNF was inhibited. When retreated by rhBDNF, BDNF knockdown cells showed less apoptotic or more
proliferative and invasive.
Conclusions: Our data show that BDNF probably facilitates the tumorigenesis of lung SCC and ADC. The expression of
BDNF mRNA variant IX is probably more helpful to the upregulation of BDNF in SCC, and intervening the production
of BDNF could be a possible strategy to lung cancer therapy.
Keywords: BDNF, Expression, Knockdown, Lung SCC, ADC
* Correspondence: labczs@mail.cmu.edu.cn
1Center of Laboratory Technology and Experimental Medicine, China Medical
University, No.77 Puhe Road, Shenyang North New Area, Shenyang, Liaoning,
People’s Republic of China
Full list of author information is available at the end of the article
© 2016 Zhang et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Zhang et al. BMC Cancer  (2016) 16:171 
DOI 10.1186/s12885-016-2218-0
Background
Lung cancer is a common and serious malignant tumor
worldwide, and the incidence and mortality of lung can-
cer are increasing every year. Lung SCC and ADC are
the primary histological classification of lung cancer and
included in this study. The outcome of patients with lung
cancer mainly depends on tumor development and evolu-
tion, which are closely associated with the expression of
tumor related genes. More research should be performed
to identify the regulatory function of those genes.
Brain-derived neurotrophic factor (BDNF) is a member
of the neurotrophin family. BDNF plays an important role
in the development and regeneration of the neurons. Bind-
ing of BDNF to its major receptor, tropomyosin-related re-
ceptor kinase B (TrkB) with high affinity and specificity [1],
leads to the activations of various downstream signalings,
including PI3K/AKT, RAS/ERK, PLC/PKC, AMPK/ACC
and JAK/STAT pathways [2]. BDNF and TrkB have been
reported to promote tumorigenesis and progression in sev-
eral human malignancies such as neuroblastoma [3], breast
[4], lung [5], prostate [6], and colon cancer [7]. Studies
have shown that BDNF/TrkB signaling was involved in
proliferative [8] or invasive properties [9]. These findings
indicated that BDNF/TrkB signaling was closely associated
with tumor progression [10], and it has emerged as a po-
tential therapeutic target [11].
Researches focused on the function of BDNF/TrkB in
lung cancer were also performed in recent years. Ricci A
and his colleagues recognized the importance of neuro-
trophins and receptors family for human lung cancer [12].
It has been reported that the expression of TrkB and
BDNF was associated with poor prognosis in non-small
cell lung cancer [13] and TrkB/BDNF signaling pathway
could be a therapeutic target for pulmonary large cell neu-
roendocrine carcinoma [14]. We previously demonstrated
the involvement of the BDNF/TrkB pathway in the inva-
sion of A549 cells [15].
However, despite the considerable amount of studies
on BDNF have been reported in human cancer, here we
investigated the function of BDNF in lung SCC and ADC.
We reported here that the overexpression of BDNF was
common in SCC and ADC, particularly correlated with
histological type and T stage. We also reported that the
expression and secretion of BDNF were more extensive
in lung cancer cells. Moreover, the BDNF mRNA variant
containing exon IX was important to the higher expression
in SCC cells, and BDNF was critical to the proliferation
and invasion of lung cancer cells.
Methods
Lung cancer samples
110 cases of lung SCC and ADC samples were all from
the Pathology Department in China Medical University.
The ethical approval was given by the Medical Research
Ethics Committee of China Medical University. All partic-
ipants were provided the written informed consent before
enrolment in this study and the agreements were ob-
tained. The enrolled cases did not receive any chemother-
apy or radiation therapy before curative surgical resection.
Formalin-fixed paraffin-embedded sections of tumor were
stained with hematoxylin and eosin (HE), and diagnosed
according to the guidelines of classification of lung and
pleural tumors (2004) and the TNM staging system (1997)
of WHO by two senior pathologists. The histological type,
differentiation, stage and lymph node metastasis were
determined accordingly and summarized in Table 1.
Immunohistochemistry
110 paraffin sections of lung SCC and ADC were depar-
affinized and rehydrated routinely. The sections were
heated in 0.1 mol/L Tris–HCl at pH10 in an autoclave
sterilizer for 1 min for the recovery of antigen. The sec-
tions were incubated with 3 % H2O2 to eliminate en-
dogenous peroxidase, followed by 5 % goat serum to
avoid unspecific binding of antibody at 37 °C for 1 h.
The sections were then incubated with primary mouse
monoclonal antibody specific for BDNF (1:100 dilution,
Abcam) overnight at 4 °C. The next day, sections were
incubated with goat anti-mouse IgG and streptavidin-
peroxidase (SP) complex at 37 °C for 40 min (SP kit,
Maxim, China), and then developed with 3,3′-diamino-
benzidine (DAB). Neuroblastoma was used as positive
control for BDNF, and nonimmune goat IgG instead of
BDNF antibody was used as negative control. Two senior
pathologists assessed the immunostained sections separ-
ately. The distinguishing brown particles in cytoplasm were
regarded as BDNF-positive. The intensity of BDNF immu-
nostaining (0 = negative, 1 = weak, 2 = intense) and the
percentage of positive tumor cells (≤50 % = 1, >50 % = 2)
were evaluated in at least 5 high power fields (×400
magnification). The scores of each tumor section were
multiplied to generate a final score of 0, 1, 2 or 4, and
the samples were finally defined as high expression:
score >2; or low expression: score ≤2 (including negative:
score 0).
Cells culture and transfection
Human bronchial epithelial cells (HBE), lung SCC cells
(SK-MES-1, LK2) and ADC cells (A549, LTE) were cryo-
preserved in our department. HBE, A549 and LTE cells
were cultured in RPMI1640 (Gibco, USA), and SK, LK2
cells were cultured using DMEM (Gibco, USA), supple-
mented with 10 % fetal bovine serum (FBS), in an incuba-
tor at 37 °C with 5 % CO2. LK2 and A549 cells were
selected to perform the establishment of stable cell strain
with BDNF knockdown for their better condition and
vitality. They (50-60 % confluence) were transfected with
either BDNF-shRNA or scrambled control (Genechem,
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China) using Lipofectamin 2000 (Invitrogen, USA), ac-
cording to the manufacturer’s guidelines. The qualified
cell clones were screened by G418, and the decreased ex-
pression of BDNF was confirmed by western blot. When
indicated, those transfected cells were retreated with re-
combinant human BDNF (rhBDNF, 100 ng/mL, Peprotech,
USA). Cells were used for proteins extraction or cell bio-
logical assays as described below. The experiments for cells
were performed in triplicates.
Western blot
25 cases of fresh SCC (10) and ADC (15) were obtained
from the Pathology Department. Tissues or cells were
washed with ice-cold phosphate buffer saline (PBS) and
lysed in RIPA lysis buffer containing protease inhibitor
(Roche, USA). The homogenate was centrifuged at
15,000 g at 4 °C for 30 min. The supernatant was col-
lected and protein content was quantified by the method
of bicinchoninic acid (BCA) assay (Pierce). 60 μg of
protein sample was loaded in sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and trans-
ferred to polyvinylidene fluoride (PVDF) membrane. 5 %
bovine serum albumin (BSA) was used to block unspecific
binding of antibodies to membrane. Then the primary anti-
bodies containing mouse monoclonal anti-BDNF (1:200,
Abcam, USA) or rabbit polyclonal anti-BDNF (1:200,
Sangon, China) and anti-β-actin (1:1000, Santa Cruz,
USA) were incubated with membranes at 4 °C over
night. The membranes were then incubated with goat
anti-mouse or rabbit IgG (1:2000, ZhongShan, China)
at 37 °C for 2 h. The specific protein bands were visualized
using the enhanced chemiluminescence (ECL) method
(TranGen Biotech, China), using the DNR Imaging Sys-
tem. The Image-Pro Plus 6.0 software was used to per-
form semi-quantitative analysis of the optical density of
each band. The ratio between the optical density of BDNF
and β-actin of the same sample was used to indicate the
relative level of BDNF expression.
ELISA
Human BDNF Quantikine ELISA kit (R&D Systems,
Minneapolis, MN, USA) was used to measure the pro-
tein concentration of BDNF in the supernatant collected
by centrifugation from cultured cells for 24 or 48 h.
BDNF secretion was evaluated according to the manu-
facturer’s instructions. In general, 50 μL of sample or
standard was mixed with 100 μL assay diluent and added
to the microplate wells, incubating at room temperature
for 2 h. The mixture was incubated at room temperature
for another 1 h after adding 100 μL of BDNF conjugate.
The development reaction was performed with 200 μL
of substrate solution after several washes. Then the ab-
sorbance value was shown by a microplate reader at
450 nm, with a calibration wavelength of 570 nm.
Reverse transcription polymerase chain reaction
Total RNA of cells was extracted using Trizol (Invitrogen,
USA). cDNA was produced by reverse transcription reac-
tion of 5 μg total RNA using GoScript Reverse Transcrip-
tion System (Promega, USA). The primer sequences used
in this study were listed in Table 2. The lengths of the
PCR products using the reverse primer hBDNF_IXbAS in
combination with the following forward primers were
hBDNF_IVS, 412 bp; hBDNF_VIS, 494, 387, and 369 bp;
Table 1 Statistical analysis on the correlations between BDNF expression by immunohistochemical staining in 110 lung cancer
samples and the clinicopathological parameters
Clinicopathological Characteristics Cases (n = 110) Low expression (n = 49) High expression (n = 61) p-value
Histological type
Squamous cell carcinoma 53 20 33 0.017
Adenocarcinoma 57 29 18
Grade
well-moderate 76 31 45 0.236
poor 34 18 16
Stage
I-II 72 36 36 0.113
III 38 13 25
Tumor size and extension
T1-T2 75 39 36 0.021
T3 35 10 25
Lymph node metastasis
No 68 30 38 0.532
Yes 42 19 23
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and hBDNF_IXS, 597 and 363 bp, respectively (as de-
scribed by Prof. Pruunsild) [16]. PCR conditions were set
as follows: initial denaturation at 94 °C for 2 min; 35 cycles
of denaturation at 94 °C for 30s; annealing at appropriate
temperature listed in the Table 1 for 30s; elongation at
72 °C for 30s; final elongation at 72 °C for 5 min. The PCR
conditions for β-actin were similar to that for BDNF
mRNA variants, except for annealing at 55 °C and 30 cycles.
The specific bands were visualized using the ChemiImager
5500 (Alpha Innotech, USA), and the Image-Pro Plus 6.0
software was used for the semi-quantitative analysis of the
optical density of each band.
CCK-8 assay
The cell proliferation was evaluated using CCK-8
(DOJINDO, Japan) assay, which was lasted for 5 days.
Cells were digested, counted and adjusted to 1 × 103/100 μL,
and seeded in five 96-well plates simultaneously. Every day,
a random plate was selected for the measurements of ab-
sorbance, and cells in other plates were cultured for the rest
of days. The absorbance of each well was measured in a mi-
croplate reader (SpectraMax Plus 384, USA) at 450 nm at
4 h after 10 μL CCK-8 was added. The average absorbance
(Y-axis) and time (X-axis) were applied to draw the cell
growth curves. Data indicated are mean value of three indi-
vidual wells.
Cell apoptosis assay
The Annexin V-FITC (fluorescein isothiocyanate) apoptosis
detection kit (BD Biosciences, USA) was used to monitor
cell apoptosis by flow cytometry, according to the man-
ufacturer’s protocol. Cells were rinsed twice using ice-
cold PBS and resuspended in 1 × binding buffer (1 ×
106/mL). 100 μL (1 × 105) cells were gently mixed with
5 μL PI and 5 μL Annexin V-FITC, and incubated for
15 min at room temperature in dark. Cells were supple-
mented with another 400 μL 1 × binding buffer, and ex-
amined in a flow cytometer. Data are representative of
three individual tests.
Cell invasion analysis
The 24-well Transwell chamber (Costar, USA) was used
to perform cell invasion assay. Cells were digested,
counted and adjusted to 1 × 104, and seeded in the upper
chamber with an 8 μm pore size insert in a 24-well plate.
The inserts were precoated with Matrigel (1:6 dilution,
BD Biosciences) and cells were cultured in medium con-
taining 1 % FBS. They were driven to invade Matrigel and
migrate towards medium containing rhBDNF (100 ng/mL)
or 10 % FBS in the bottom chamber for 24 h. After remov-
ing the detained cells on the upper surface of membrane
with a cotton tip, the migratory cells on the under surface
were fixed using 4 % paraformaldehyde and stained with
hematoxylin. The number of invaded cells was counted in
5 randomly selected fields under a microscope of 200×
power. Data expressed are mean value of three individual
wells.
Statistical analysis
SPSS 13.0 statistical analysis software was used to per-
form data statistics. χ2-test was applied to evaluate the
correlations of BDNF expression and clinicopathological
parameters for the immunohistochemical results. The
t-test was used to evaluate the difference of BDNF ex-
pression between tumors and non-tumor counterparts.
One-way ANOVA was used to evaluate the differences
between variously treated cells. All data were shown as
mean ± SD and results were regarded statistically sig-
nificant when the p value <0.05.
Results
BDNF expression in specimens of lung SCC and ADC by
Immunohistochemistry
Weak expression of BDNF was shown in the cytoplasm
of bronchial epithelial cells (Fig. 1a), and no expression
was found in alveolar epithelium (Fig. 1d). BDNF immu-
nostaining was observed in the cytoplasm of cancer cells.
Positive BDNF was found in 79 (71.8 %) neoplastic sec-
tions. We considered that 61 (55.5 %) cases were high
expression (scores >2) and 49 cases (44.5 %) were low
expression (scores ≤2), as elaborated in Methods. BDNF
Table 2 The primers of 3 BDNF mRNA variants and β-actin used in this study
mRNA Sequences Annealing temperature
hBDNF_IVS forward 5′-GCTGCAGAACAGAAGGAGTACA-3′ 61.8 °C
reverse 5′-GTCCTCATCCAACAGCTCTTCTATC-3′
hBDNF_VIS forward 5′-GGCTTTAATGAGACACCCACCGC-3′ 63.3 °C
reverse 5′-GTCCTCATCCAACAGCTCTTCTATC-3′
hBDNF_IXS forward 5′-TTTCTCGTGACAGCATGAGCAG-3′ 60.6 °C
reverse 5′-GTCCTCATCCAACAGCTCTTCTATC-3′
β-actin forward 5′-TGAGTCTCCTTTGGAACTCTGC-3′ 55 °C
reverse 5′-TAGCAACGTACATGGCTGGG-3′
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was reported to be correlated with tumor growth, inva-
siveness and metastasis, so the association between BDNF
expression and clinicopathological characteristics was
analyzed statistically, as shown in Table 1. BDNF im-
munostaining was stronger in tumors of SCC (vs. ADC,
p = 0.017) and T3 (vs. T1-T2, p = 0.021). And no signifi-
cant difference of BDNF expression was found between
tumors with various differentiation (well-moderate vs
poor, p = 0.236), stage I-II (vs. III, p = 0.113) and lymph
node status (metastasis vs no metastasis, p = 0.532).
BDNF expression in 25 cases of tumor and paired non-tumor
by western blot
Western blot analysis was used to detect BDNF expres-
sion in 10 SCC and 15 ADC cases of lung cancer and
non-tumorous tissue distant from the primary tumor of
the same case. The overexpression of BDNF was found
in 20 tumor samples in comparison with the non-tumor
counterparts (p = 0.000). The specific bands for BDNF of
eight samples are shown in Fig. 2a, and the relative op-
tical density of the tumor (T) and non-tumor (N) tissues
of the same patient was measured and expressed graph-
ically (Fig. 2b).
BDNF expression in HBE and four lung cancer cell lines by
western blot
The expression of BDNF was also examined in HBE,
two lung SCC (SK, LK2) and two ADC (A549, LTE) cell
lines using western blot. We showed that the expression
of BDNF represented by the specific bands of 28 kDa
was almost undetectable in HBE cells. However, the IOD
indicative of BDNF protein level was excessively high in
lung cancer cells (Fig. 3). Statistical analysis confirmed
that SK and LK2 cells expressed more BDNF than A549
and LTE cells (p = 0.000).
The secretory BDNF in supernatants of cells by ELISA
BDNF is a secretory cytokine, which is prepared by
tumor cells and promotes growth and survival of them-
selves [17]. In the present study, BDNF secreted by HBE,
SK, LK2, A549 and LTE cells was measured by ELISA
assays. Our results showed that BDNF in supernatant of
HBE and A549 cells at 24 or 48 h were not detected.
Fig. 1 BDNF expression in bronchial and alveolar epithelium, SCC and ADC tissues by immunohistochemical staining. Hematoxylin was counterstained
for nuclei. Weak expression of BDNF was shown in bronchial epithelial cells (a), and no expression was found in alveolar epithelium (d). SCC showed
positive expression of BDNF (b and c), including the moderate staining of T1 stage (B), and intense staining of T3 stage (c). ADC showed
positive expression of BDNF (e and f), including the moderate staining of T1 stage (e), and intense staining of T3 stage (f). (magnification, 400×)
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BDNF in supernatant of LTE cells was undetected at
24 h, which was 30.5 ± 18.0 pg/mL at 48 h. The concen-
tration of BDNF in supernatant of SK and LK2 cells
were 38.3 ± 15.5 and 29.0 ± 11.6 pg/mL at 24 h, and
150.5 ± 54.0 pg/mL and 212.0 ± 88.0 pg/mL at 48 h, re-
spectively. These results indicated that more BDNF was
produced by SK and LK2 cells.
The expression of BDNF mRNA variants in cells by RT-PCR
BDNF has multiple alternative splicing variants and
plays diverse biological functions in mammals, including
neuronal survival, cell differentiation and tumor devel-
opment. The multiple BDNF alternative splicing variants
are formed to achieve precise temporal and spatial ex-
pression of functional BDNF. The expressions of BDNF
mRNA variants containing exons IV, VI and IX were se-
lected according to previous reports [16], and investigated
in this study. The mRNA levels were found identical in
variants containing exons IV and VI in cells examined.
However, the mRNA level was different in variants con-
taining the exon IX (Fig. 4). Statistical analysis proved that
SK and LK2 cells expressed more BDNF variant IX than
HBE, A549 and LTE cells (p = 0.000).
Supppression of cell proliferation by BDNF-shRNA
LK2 and A549 cells were transfected with specific shRNA
to explore the function of BDNF on cell proliferation,
apoptosis and invasion. Fig. 3b confirmed the decreased
expression of BDNF in transfected cells. We found that
2 days after LK2 were seeded, and 3 days after A549 cells
were seeded, the absorbance in BDNF-shRNA, scrambled
and control groups was statistically different (p = 0.025
and p = 0.002). According to the cell growth curves during
the 5 days, we found that both LK2 and A549 cells with
BDNF-shRNA transfection showed a decreased prolifera-
tive activity compared with other groups. When retreated
with rhBDNF, BDNF knockdown LK2 or A549 cells
showed enhanced proliferative abilities (Fig. 5). These re-
sults showed that suppression of BDNF expression inter-
fered with the proliferation of LK2 and A549 cells.
More apoptotic cells with BDNF-knockdown
Cell apoptosis was examined in this study to investigate
whether BDNF facilitated overgrowth of cells by apoptosis
inhibition. The apoptotic rates of LK2 cells in BDNF-
shRNA, scrambled and control groups were 30.8 ± 1.9 %,
16.3 ± 2.7 % and 9.8 ± 1.6 % (p = 0.000; Fig. 6a, b, c). The
apoptotic rates of A549 cells in the above groups were
21.7 ± 2.3 %, 9.1 ± 1.5 % and 4.1 ± 1.3 % (p = 0.000;
Fig. 6e, f, g). When retreated with rhBDNF, the apop-
totic LK2 or A549 cells with BDNF knockdown were
apparently reduced (Fig. 6d and h). Our results showed
that apoptosis was significantly induced in BDNF shRNA-
transfected cells.
Fig. 2 a Expression of BDNF was detected by western blot in paired
tumors (T) and non-tumors (N) from 8 of 25 lung cancer patients,
and 4 of which were SCC (T1, T3, T5, T7), the other 4 were ADC
(T2, T4, T6, T8). It was shown that BDNF expression was up-regulated
in tumor compared with non-tumor of the same patient. β-actin was
used as a reference control to ensure the equal protein quantity in all
lanes. b The ratio between the optical density of BDNF and β-actin of
the same sample was calculated and plotted. The significant difference
of BDNF between tumors (T) and non-tumors (N) were analyzed
statistically. BDNF immunoreactivity is greater in neoplastic tissues
Fig. 3 a BDNF expression in HBE cells, two SCC cells (SK and LK2) and two ADC cells (A549 and LTE) by western blot analysis. The ratio between
the optical density of BDNF and β-actin of the same cells was used to indicate the relative level of BDNF expression. The expression of BDNF was
rare in HBE cells, and that was much higher in other 4 lung cancer cells. b The decreased expression of BDNF by specific shRNA was shown in
LK2 or A549 cells. β-actin was used as a reference control to ensure the equal protein quantity in all lanes. The experiments for each cell line were
completed in triplicates
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Down-regulation of BDNF on the invasive potential of
shRNA-transfected cells
Since BDNF overexpression was common in more ag-
gressive tumours, the stable cells of LK2 or A549 with
low expression of BDNF were used to determine its con-
tribution to cell invasion. The numbers of invasive LK2
or A549 cells in BDNF-shRNA or scrambled shRNA
transfected and control groups were 31.3 ± 4.2, 72.0 ±
4.4, 65.7 ± 7.0 and 29.7 ± 4.2, 63.0 ± 7.2, 66.0 ± 7.2, re-
spectively (p = 0.000; Fig. 7a-c and e-g). However, in the
group of LK2 or A549 cells retreated with rhBDNF,
chemotaxis of rhBDNF was shown as 45.7 ± 4.7 or 47.0 ±
5.6, which was both more than BDNF-shRNA group (p =
0.000; Fig. 7d and h). These results showed that BDNF
knockdown significantly attenuated the invasive ability of
transfected cells.
Discussion
Brain-derived neurotrophic factor, also known as BDNF,
is a member of the “neurotrophin” family of growth fac-
tors, helping to support the survival of existing neurons,
and encourage the growth and differentiation of new
Fig. 4 The expression of BDNF mRNA variants respectively containing exons IV, VI and IX in HBE, SK, LK2, A549 and LTE cells by RT-PCR. BDNF mRNA
levels remained invariable in variants containing exons IV and VI. SK and LK2 cells showed much higher level of BDNF mRNA variant containing exon
IX, compared with HBE, A549 and LTE cells. β-actin was used as a loading control to assure equal amounts of protein in all lanes. The experiments for
each cell line were repeated at least three times
Fig. 5 The effects of BDNF knockdown or retreatment on cell proliferation. Cell growth curves showed that both LK2 (left panel) and A549 (right panel)
cells with BDNF-shRNA transfection presented a decreased proliferative activity compared with other groups during the 5 days. Furthermore, both cells
proliferation was facilitated after rhBDNF retreatment. Data are indicated as mean ± SD of three replicates
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Fig. 6 The effects of BDNF knockdown or retreatment on cell apoptosis. The apoptotic rate of BDNF knockdown cells was evidently increased or
decreased with rhBDNF treatment. a LK2 cells untreated. b scrambled shRNA transfected LK2 cells. c LK2 cells of BDNF knockdown. d LK2 cells
with rhBDNF retreatment. e A549 cells untreated. f scrambled shRNA transfected A549 cells. g A549 cells of BDNF knockdown. h A549 cells with
rhBDNF retreatment. The data are shown as mean ± SD of three individual experiments
Fig. 7 The effects of BDNF knockdown or retreatment on cell invasion. a LK2 cells untreated. b scrambled shRNA transfected LK2 cells. c cell invasion
was inhibited in BDNF-shRNA transfected LK2 cells. d more invasive cells were shown in rhBDNF treated BDNF-knockdown LK2 cells. e A549 cells
untreated. f scrambled shRNA transfected A549 cells. g the number of invasive A549 cells with BDNF-shRNA transfection was reduced. h cells
were more invasive after rhBDNF treatment. The values are mean ± SD of three independent experiments
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neurons and synapses [18]. The up-regulation of BDNF
was found in a variety of primary human tumors, in-
cluding breast cancer [19], hepatocellular carcinoma
[20], and bladder cancer [21], suggesting a significant
role of BDNF in the development and progression of
cancer. The primary receptor for BDNF, TrkB is critical in
lung cancer development. A recent study by Sinkevicius
KW found that the receptor TrkB deficiency significantly
reduced metastasis of a lung adenocarcinoma model [22].
Götz R also revealed that the cooperation of TrkB and
EGFR signaling enhances migration and dispersal of lung
tumor cells [23].
In this study, we evaluated the expression of BDNF in
lung SCC and ADC. We found a statistical evidence of
BDNF up-regulation in lung cancer, compared with their
non-tumor counterparts. BDNF overexpression was found
extensively in most of neoplastic tissues, supporting its
potential role in lung tumorigenesis. We also examined
110 FFPE sections of lung SCC and ADC by means of im-
munohistochemistry to reveal the clinical significance of
BDNF for lung cancer. We found that tumors with high
BDNF expression had an advanced T stage, and SCC
expressed more BDNF. It has been reported that the posi-
tive TrkB staining in SCC correlated specifically with im-
proved disease-specific survival and overall survival [24].
Furthermore, the lineage transition in SCC and ADC of
lung cancer was presumed for the clinical observation of
mixed components in adenosquamous carcinoma re-
cently. Studies have shown the evidence for the plasticity
of lung cancer, that the transdifferentiation from SCC to
ADC under implicated circumstances [25, 26]. However,
the significance of BDNF in lung SCC still required inten-
sive research. These results suggested that BDNF was crit-
ical in the tumorigenesis of lung cancer. Further studies
and more samples are required to investigate the relation-
ship between BDNF and TrkB in lung SCC and ADC.
It has been reported that BDNF is a secretory protein,
produced by tumor cells to promote their growth and
survival [27]. Therefore, BDNF in culture supernatant
was assessed in HBE and four lung cancer cell lines. As
we expected, the SCC cells of LK2 and SK had more se-
cretion of BDNF in supernatant, compared to HBE and
the ADC cells of A549 and LTE. We also examined the
expression of BDNF by western blot in HBE and other
lung cancer cells. We showed that BDNF expression
represented by the specific protein band of 28 kDa was
quite weak in HBE cells, while SK and LK2 cells
expressed higher level of BDNF, compared with A549
and LTE cells. However, besides the specific BDNF bands,
various protein bands were also found in cells, which
were not present in tissue samples. We presumed that
those unexpected bands were proteins probably con-
taining its precursor proBDNF [28], or some unknown
BDNF protein subtypes came from spliced mRNA
variants, which requires further identifying and recog-
nizing investigations.
It has been reported that 17 splice variants when BDNF
gene was transcripted into mRNAs, and each variant is
expressed in specific tissues and cells. Studies have shown
that human BDNF alternative transcripts are expressed in
a tissue-specific manner. According to the previous re-
search, three BDNF mRNA transcripts containing exons
IV, VI or IX, which are expressed relatively higher in lung
tissue, were selected to be examined in this study to evalu-
ate the significance of the above variants to the higher ex-
pression of BDNF in lung cancer cells. We found that the
mRNA level of variants IV and VI was identical, only the
mRNA level of variant IX was different among cells exam-
ined. SCC cells of SK and LK2 with more expression of
BDNF protein had higher level of the mRNA variant IX.
These results suggested that variant IX was responsible
for the higher expression and secretion of BDNF protein,
which was probably helpful to the development of SCC.
We have previously supported that blocking of recep-
tor TrkB signaling inhibited invasion of A549 cells. In
this study, we explored the function of BDNF on prolif-
eration, apoptosis and invasion by specific shRNA trans-
fection in LK2 and A549 cells. It was confirmed that
blocking of BDNF expression inhibited cell proliferation
and invasion, and promoted cell apoptosis. Our data indi-
cate that BDNF promotes cell proliferation and invasion,
and silencing BDNF probably confers the disadvantage to
the growth of lung cancer cells.
We have previously confirmed that TrkB was overex-
pressed in lung cancer, BDNF facilitated A549 cell inva-
sion by inducing phosphorylation of Pyk2-tyr402, which
is a newly found signaling associated with invasion of
lung cancer cells. Pyk2 is also called Ca2+-dependent
tyrosine kinase, which is involved in the regulation of
Ca2+ flow-mediated signaling activations and cell migration.
Therefore, the Ca2+/Pyk2 signaling involved in cell invasion
were investigated recently. The LK2 and A549 cells with
shBDNF transfection were stimulated by recombined hu-
man BDNF. We observed the elevated Ca2+ concentration
and Pyk2-tyr402 phosphrylation, and cells invasion was also
enhanced. Ca2+ concentration was significantly elevated
after BDNF stimulation, and that was much lower in
cells pretreated with endoplasmic reticulum Ca2+ channel
protein IP3R blocker 2-APB than control cells, which indi-
cated that BDNF promoted Ca2+ release from endoplas-
mic reticulum through IP3R. We are proposing to focus
on Ca2+ signaling associated with invasion of lung cancer
cells in our future studies.
Conclusion
In conclusion, our study demonstrated that overexpression
of BDNF was evident in lung SCC and ADC, and the in-
creased expression of BDNF protein in SCC cells was
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closely correlated with higher level of its spliced mRNA
variant containing exon IX. Knockdown of BDNF using
RNA interfering showed the decreased activity of prolifera-
tion and invasion in LK2 and A549 cells, which indicated
that BDNF may play a decisive role in tumorigenesis of
lung SCC and ADC, whose growth and survival were prob-
ably facilitated by BDNF secreted by themselves. The sup-
pression of BDNF may provide a significant target for
inhibitory strategies for the development of lung cancer,
which requires further investigations.
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